multiple sclerosis

Sanofi SA (NASDAQ:SNY) reported Wednesday new data from a Phase 2 study in relapsing multiple sclerosis. What Happened: The company’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. It also demonstrated favorable tolerability after nearly one year in...

Among a biotech space bursting with innovation, one company stands out as it is developing two assets at once: a ready-for-market drink that can take someone from a drinking state to mental and physical composure in record time and a potential breakthrough therapy for Multiple...

Cannformatics, an early-stage biotechnology company, has unveiled a groundbreaking advancement in the field of medical cannabis treatment for Autism Spectrum Disorder (ASD). Their recent publication in Nature's Scientific Reports highlights the use of Cannabis-Responsive (C-Res) biomarkers and...

Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials. Spasticity is characterized by increased muscle stiffness and spasms, which can be...

FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first cohort of participants on its Phase 1 study assessing Lucid-21-302, or Lucid-MS, has completed...

In August 2011, Tim Cook was named the CEO of Apple Inc following the death of company CEO and co-founder Steve Jobs. Through the years, Cook has guided Apple to become one of the biggest companies in the world, with market capitalization now over $2.6 trillion. Here are five things you...

FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis. The biopharma company is currently developing three drug candidates through its wholly-owned...

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, its tolerizing vaccine for multiple sclerosis (MS). PAS002 vaccine construct encodes GlialCAM, a molecule found in the brain's white matter that is attacked in...

Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation related to its conduct before 2015. Qui tam is a type of whistleblower...

Two Rhode Island cannabinoid research laboratories are suing the DEA for standing in the way of what they consider to be the crucial development of pharmaceutical-grade cannabis products for use in clinical trials for the treatment of Multiple Sclerosis and...

Novartis AG (NYSE: NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability...

A study funded by the National MS Society recently discovered that nearly one million people are living with Multiple Sclerosis (MS) in the United States. Recognized as an unpredictable disease that impacts the brain and spinal cord, there is currently no cure for MS...

Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced a new chemical entity (NCE) development program and named Massachusetts-based Hooke Laboratories as its research partner. The biotechnology company is focused on the research and discovery of treatments for psychiatric and neurological...

Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling, the court also affirmed a decision by a review board within the U.S. Patent and Trademark office. "Viewing the...

The European Commission has approved Biogen Inc's (NASDAQ: BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS). Vumerity is next-generation fumarate with the established efficacy and well-characterized safety of Tecfidera (...